Cagent Vascular

Saving Limbs Where Others Stop: Cagent Vascular Announces Landmark Peer-Reviewed Data Demonstrating Safety and Efficacy of Serration Remodeling Therapy in the Most Challenging Arteries Below-the-Ankle Largest published series of specialty technology use in inframalleolar vessels shows

Financing supports clinical advancement and commercialization of the company’s dual-modality IVL platform, with proceeds funding peripheral commercial launch and coronary program development WAYNE, Pa.--( BUSINESS WIRE )--Cagent Vascular, Inc., a leader in endovascular technologies, today annou

Latest Cagent Vascular news, media and press releases: Serranator product updates, clinical study results, funding announcements, and industry recognition.

Cagent Vascular adds 7.0mm and 8.0mm Serranator sizes, extending serration technology to iliac, SFA, and AV fistula for large-vessel PAD management.

Cagent Vascular offers career opportunities and focuses on peripheral innovation and improving patient care.

The page presents Cagent Vascular's leadership team and describes its work advancing endovascular technology for improved patient outcomes.

Cagent Vascular is an endovascular technology company focused on advancing PAD treatments and improving patient outcomes.

Contact Cagent Vascular for product information, clinical support, reimbursement inquiries, or general questions.

Cagent Vascular pioneers Serration Remodeling Therapy (SRT) creating controlled lines of weakness to release the internal elastic lamina, reducing recoil and increasing luminal gain in PAD angioplasty.

The page describes Cagent Vascular's privacy practices, data protection, user rights, information security, and options for managing data privacy.